{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:09Z","timestamp":1793383149754,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004915","name":"Nyreforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009908","name":"Grosserer L. F. Foghts Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009908","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020219","name":"Helen og Ejnar Bj\u00f8rnows Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006197","name":"Fonden til L\u00e6gevidenskabens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dapagliflozin and finerenone reduce albuminuria and slow CKD progression, but additive effects remain unstudied. We compared their individual and combined efficacy and safety in patients with non-diabetic CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In an open-label, randomized clinical trial, we included patients aged 18\u201380 on maximal tolerated ACE inhibitor or angiotensin receptor blocker with eGFR 25\u201345\u00a0mL\/min\/1,73\u00a0m2 and albuminuria 150\u20132000\u00a0mg\/g. Participants received either finerenone 20\u00a0mg\/day or dapagliflozin 10\u00a0mg\/day for four weeks, followed by combination therapy for four weeks. Data were collected at baseline, 4 and 8 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty patients (10 per group) with a mean mGFR of 34\u00a0mL\/min\/1,73 m2 and a mean urine albumin creatinine ratio (UACR) of 469\u00a0mg\/g were included. Finerenone alone or in addition to dapagliflozin resulted in \u221224% (95% CI, \u221236% to \u221211%) and \u221234% (95% CI, \u221247% to \u221218%) change in UACR, respectively. Dapagliflozin alone or in addition to finerenone resulted in \u22128% (95% CI, \u221222 to 9%) and \u221210% (95% CI, \u221228% to 12%) change in UACR, respectively. Overall, UACR change after 8 weeks was \u221236% (95% CI, \u221246% to \u221224%). After 8 weeks, systolic blood pressure and mGFR were reduced by 10\u00a0mmHg (95% CI, 6\u201313\u00a0mmHg) and 7\u00a0mL\/min\/1,73 m2 (95% CI, 5\u20138\u00a0mL\/min\/1,73 m2). Adverse effects were minimal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of finerenone and dapagliflozin was safe and significantly reduced albuminuria. The effect of combination therapy was at least equal to the calculated, combined effect of each of the drugs, suggesting an additive effect on albuminuria. Larger studies assessing long-term effects and safety are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfad249","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T17:39:12Z","timestamp":1695836352000},"source":"Crossref","is-referenced-by-count":51,"title":["Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6367-338X","authenticated-orcid":false,"given":"Frederik Husum","family":"M\u00e5rup","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, Aarhus University Hospital , Aarhus , Denmark"},{"name":"Department of Biomedicine, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Bjergskov","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Aarhus University Hospital , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Aarhus University Hospital , Aarhus , Denmark"},{"name":"Department of Biomedicine, Aarhus University , Aarhus , Denmark"},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"2024020711371575600_bib1","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.3390\/ijms24032803","article-title":"Therapeutic advances in diabetic kidney disease","volume":"24","author":"Georgianos","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2024020711371575600_bib2","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib3","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024020711371575600_bib6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024020711371575600_bib7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2024020711371575600_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2024020711371575600_bib9","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2024020711371575600_bib10","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work G","year":"2022","journal-title":"Kidney Int"},{"key":"2024020711371575600_bib13","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2024020711371575600_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024020711371575600_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, Dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024020711371575600_bib16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of Dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024020711371575600_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024020711371575600_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024020711371575600_bib19","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024020711371575600_bib20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1053\/j.ajkd.2013.06.016","article-title":"Day-to-day variability in spot urine albumin-creatinine ratio","volume":"62","author":"Naresh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2024020711371575600_bib21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024020711371575600_bib22","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2024020711371575600_bib23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40262-022-01124-3","article-title":"Dose-exposure-response analysis of the nonsteroidal mineralocorticoid receptor antagonist finerenone on UACR and eGFR: an analysis from FIDELIO-DKD","volume":"61","author":"Goulooze","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2024020711371575600_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"2024020711371575600_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024020711371575600_bib26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2024020711371575600_bib27","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2024020711371575600_bib28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","article-title":"Nongenomic vascular action of aldosterone in the glomerular microcirculation","volume":"14","author":"Arima","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2024020711371575600_bib29","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMe2031382","article-title":"Finerenone - halting relative hyperaldosteronism in chronic kidney disease","volume":"383","author":"Ingelfinger","year":"2020","journal-title":"N Engl J Med"},{"key":"2024020711371575600_bib30","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024020711371575600_bib31","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"2024020711371575600_bib32","author":"Bayer","year":"2025","journal-title":"A Trial to Learn How Well Finerenone Works and How Safe It Is in Adult Participants with Non-diabetic Chronic Kidney Disease"},{"key":"2024020711371575600_bib33","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad249\/52248810\/sfad249.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad249\/56610585\/sfad249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/1\/sfad249\/56610585\/sfad249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:38:30Z","timestamp":1707287910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfad249\/7283166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad249","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,9,26]]},"article-number":"sfad249"}}